Lonza Group AG
SIX:LONN

Watchlist Manager
Lonza Group AG Logo
Lonza Group AG
SIX:LONN
Watchlist
Price: 549.2 CHF 0.26% Market Closed
Market Cap: 37.8B CHF
Have any thoughts about
Lonza Group AG?
Write Note

Intrinsic Value

The intrinsic value of one LONN stock under the Base Case scenario is 614.03 CHF. Compared to the current market price of 549.2 CHF, Lonza Group AG is Undervalued by 11%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

LONN Intrinsic Value
614.03 CHF
Undervaluation 11%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Lonza Group AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for LONN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about LONN?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Life Sciences Tools & Services Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Lonza Group AG

Provide an overview of the primary business activities
of Lonza Group AG.

What unique competitive advantages
does Lonza Group AG hold over its rivals?

What risks and challenges
does Lonza Group AG face in the near future?

Has there been any significant insider trading activity
in Lonza Group AG recently?

Summarize the latest earnings call
of Lonza Group AG.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Lonza Group AG.

Provide P/S
for Lonza Group AG.

Provide P/E
for Lonza Group AG.

Provide P/OCF
for Lonza Group AG.

Provide P/FCFE
for Lonza Group AG.

Provide P/B
for Lonza Group AG.

Provide EV/S
for Lonza Group AG.

Provide EV/GP
for Lonza Group AG.

Provide EV/EBITDA
for Lonza Group AG.

Provide EV/EBIT
for Lonza Group AG.

Provide EV/OCF
for Lonza Group AG.

Provide EV/FCFF
for Lonza Group AG.

Provide EV/IC
for Lonza Group AG.

Show me price targets
for Lonza Group AG made by professional analysts.

What are the Revenue projections
for Lonza Group AG?

How accurate were the past Revenue estimates
for Lonza Group AG?

What are the Net Income projections
for Lonza Group AG?

How accurate were the past Net Income estimates
for Lonza Group AG?

What are the EPS projections
for Lonza Group AG?

How accurate were the past EPS estimates
for Lonza Group AG?

What are the EBIT projections
for Lonza Group AG?

How accurate were the past EBIT estimates
for Lonza Group AG?

Compare the revenue forecasts
for Lonza Group AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Lonza Group AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Lonza Group AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Lonza Group AG compared to its peers.

Compare the P/E ratios
of Lonza Group AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Lonza Group AG with its peers.

Analyze the financial leverage
of Lonza Group AG compared to its main competitors.

Show all profitability ratios
for Lonza Group AG.

Provide ROE
for Lonza Group AG.

Provide ROA
for Lonza Group AG.

Provide ROIC
for Lonza Group AG.

Provide ROCE
for Lonza Group AG.

Provide Gross Margin
for Lonza Group AG.

Provide Operating Margin
for Lonza Group AG.

Provide Net Margin
for Lonza Group AG.

Provide FCF Margin
for Lonza Group AG.

Show all solvency ratios
for Lonza Group AG.

Provide D/E Ratio
for Lonza Group AG.

Provide D/A Ratio
for Lonza Group AG.

Provide Interest Coverage Ratio
for Lonza Group AG.

Provide Altman Z-Score Ratio
for Lonza Group AG.

Provide Quick Ratio
for Lonza Group AG.

Provide Current Ratio
for Lonza Group AG.

Provide Cash Ratio
for Lonza Group AG.

What is the historical Revenue growth
over the last 5 years for Lonza Group AG?

What is the historical Net Income growth
over the last 5 years for Lonza Group AG?

What is the current Free Cash Flow
of Lonza Group AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Lonza Group AG.

Business Breakdown

Lonza Group AG is a Swiss multinational company that specializes in the life sciences and advanced materials industries, making it an integral player in the global biotechnology and pharmaceutical landscapes. Founded in 1897, Lonza has evolved from a traditional chemical manufacturer to a leading contract development and manufacturing organization (CDMO) that partners with clients to accelerate the development of innovative therapies. The company offers a wide range of services, including biopharmaceutical manufacturing, cell and gene therapy solutions, and specialized expertise in microbial products and industrial bioprocessing. As pharmaceutical companies continue to explore complex biolog...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lonza Group AG

Current Assets 4.9B
Cash & Short-Term Investments 1.4B
Receivables 1.4B
Other Current Assets 2.1B
Non-Current Assets 11.9B
Long-Term Investments 101m
PP&E 6.6B
Intangibles 4.7B
Other Non-Current Assets 488m
Current Liabilities 2.8B
Accounts Payable 468m
Other Current Liabilities 2.3B
Non-Current Liabilities 4.6B
Long-Term Debt 2.6B
Other Non-Current Liabilities 2B
Efficiency

Earnings Waterfall
Lonza Group AG

Revenue
6.7B CHF
Cost of Revenue
-4.7B CHF
Gross Profit
2B CHF
Operating Expenses
-1.1B CHF
Operating Income
874m CHF
Other Expenses
-301m CHF
Net Income
573m CHF

Free Cash Flow Analysis
Lonza Group AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Lonza reported softer performance in Q1 2024 due to batch timing and weaker demand in some divisions. However, they maintain confidence in their full-year outlook with a flat constant currency revenue growth and CORE EBITDA margins between 27% and 29%. Strong commercial demand in Biologics and significant future growth from the Roche agreement are expected to drive H2 improvements. Ongoing projects, including new facilities in Switzerland, indicate progress. The company also advanced its share buyback program and confirmed Wolfgang Wienand as the new CEO starting in summer 2024.

What is Earnings Call?
Fundamental Scores

LONN Profitability Score
Profitability Due Diligence

Lonza Group AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Net Income
Positive 3-Years Revenue Growth
Positive 3-Year Average ROE
52/100
Profitability
Score

Lonza Group AG's profitability score is 52/100. The higher the profitability score, the more profitable the company is.

LONN Solvency Score
Solvency Due Diligence

Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
High Interest Coverage
Low D/E
Long-Term Solvency
72/100
Solvency
Score

Lonza Group AG's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

LONN Price Targets Summary
Lonza Group AG

Wall Street analysts forecast LONN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LONN is 626.93 CHF with a low forecast of 328.25 CHF and a high forecast of 735 CHF.

Lowest
Price Target
328.25 CHF
40% Downside
Average
Price Target
626.93 CHF
14% Upside
Highest
Price Target
735 CHF
34% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for LONN?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for LONN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

LONN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

LONN News

Other Videos

Profile

Lonza Group AG Logo
Lonza Group AG

Country

Switzerland

Industry

Life Sciences Tools & Services

Market Cap

39.6B CHF

Dividend Yield

0.73%

Description

Lonza Group AG engages in the supply of pharmaceutical, healthcare and life science products. The company is headquartered in Basel, Basel-Stadt and currently employs 16,218 full-time employees. The company went IPO on 2002-04-03. The firm's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The firm divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Contact

BASEL-STADT
Basel
Muenchensteinerstrasse 38
+41613168111.0
www.lonza.com

IPO

2002-04-03

Employees

16 218

Officers

Chief Executive Officer
Dr. Wolfgang Wienand Ph.D.
Chief Financial Officer
Mr. Philippe Deecke
Head of Group Operations
Ms. Maria Soler Nunez
Vice President of Investor Relations
Mr. Dirk Oehlers
Group General Counsel & Company Secretary
Mr. Andreas Bohrer
Head of Ethics & Compliance, ERM and Corporate Responsibility
Ms. Kim Harrelson
Show More
Head of External Communications
Ms. Victoria Morgan
Senior Director of Global Marketing
Ms. Jennifer Clancy
Head of Corporate Environment, Health, Safety & Global Sustainability
Dr. Matthias Hofmann
President of Biologics Division
Mr. Jean-Christophe Hyvert
Show Less

See Also

Discover More
What is the Intrinsic Value of one LONN stock?

The intrinsic value of one LONN stock under the Base Case scenario is 614.03 CHF.

Is LONN stock undervalued or overvalued?

Compared to the current market price of 549.2 CHF, Lonza Group AG is Undervalued by 11%.

Back to Top